Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axsome Shares FDA Pre-NDA Minutes on AXS-05 for Alzheimer’s Agitation
Details : AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the treatment of Alzheimer’s disease agitation.
Product Name : AXS-05
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 03, 2025
Lead Product(s) : Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axsome Therapeutics Announces Successful Completion Of Phase 3 AXS-05 Program
Details : AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the treatment of Alzheimer’s disease agitation.
Product Name : AXS-05
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 30, 2024
Lead Product(s) : Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : SVB Securities
Deal Size : $225.0 million
Deal Type : Public Offering
Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock
Details : Axsome intends to use the proceeds to advance its late-stage pipeline, including AXS-05 (dextromethorphan-bupropion), a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the treatment of central nervous sy...
Product Name : AXS-05
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 30, 2023
Lead Product(s) : Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : SVB Securities
Deal Size : $225.0 million
Deal Type : Public Offering
Lead Product(s) : Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : SVB Securities
Deal Size : $225.0 million
Deal Type : Public Offering
Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock
Details : Axsome intends to use the proceeds to advance its late-stage pipeline, including AXS-05 (dextromethorphan-bupropion), a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the treatment of central nervous sy...
Product Name : AXS-05
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 28, 2023
Lead Product(s) : Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : SVB Securities
Deal Size : $225.0 million
Deal Type : Public Offering
Lead Product(s) : Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : SVB Securities
Deal Size : Undisclosed
Deal Type : Public Offering
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
Details : Axsome intends to use the proceeds to advance its late-stage pipeline, including AXS-05 (dextromethorphan), a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the treatment of central nervous system condi...
Product Name : AXS-05
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 27, 2023
Lead Product(s) : Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : SVB Securities
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AXS-05 (dextromethorphan-bupropion) is novel, oral, patent protected, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer’s disease (AD) agitation and other CNS disorders.
Product Name : AXS-05
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 28, 2022
Lead Product(s) : Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bupropion Hydrochloride,Dextromethorphan
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AUVELITY (dextromethorphan hydrobromide) is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week.
Product Name : Auvelity
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 19, 2022
Lead Product(s) : Bupropion Hydrochloride,Dextromethorphan
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axsome Therapeutics Initiates Advance-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation
Details : AXS-05 (dextromethorphan-bupropion) is a novel, oral, patent-protected, investigational NMDA receptor antagonist with multimodal activity under development for treatment of AD agitation and other CNS disorders.
Product Name : AXS-05
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 09, 2022
Lead Product(s) : Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bupropion Hydrochloride,Dextromethorphan
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AUVELITY is a novel, oral, NMDA receptor antagonist with multimodal activity approved for the treatment of MDD in adults. AUVELITY is a proprietary extended-release oral tablet containing dextromethorphan HBr (45 mg) and bupropion HCl (105 mg).
Product Name : Auvelity
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 12, 2022
Lead Product(s) : Bupropion Hydrochloride,Dextromethorphan
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AXS-05 (dextromethorphan) was generally well tolerated in the trial. The most common adverse events with AXS-05 were dizziness, nausea, dry mouth, decreased appetite, and anxiety. AXS-05 was not associated with psychotomimetic effects, weight gain, or se...
Product Name : AXS-05
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 18, 2022
Lead Product(s) : Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable